Table 1. Associations between KRAS rs61764370 and risk of ovarian and breast cancer.

For BRCA1 and BRCA2 mutation carrier analyses, cases are affected BRCA1/BRCA2 mutation carriers and controls are unaffected BRCA1/BRCA2 mutation carriers, and relative risks are estimated by hazard ratios; for other analyses, relative risks are estimated by odds ratios; ovarian cancer analyses used OCAC data adjusted for study, age, and the five European principal components; breast cancer analyses used BCAC data adjusted for study, age, and the seven European principal components; BRCA1 and BRCA2 mutation carrier analyses used CIMBA data with age as follow-up time and stratified for country; 95% CI, 95% confidence interval.

	Number		Minor allele frequency		Relative risk (95% CI)
	Cases	Controls	Cases	Controls		p-Value
Ovarian cancer
All invasive	15,357	30,816	0.0914	0.0949	0.99 (0.94–1.04)	0.74
Histology
High-grade serous	6938	30,816	0.0946	0.0949	1.04 (0.97–1.11)	0.26
Endometrioid	2151	30,816	0.0834	0.0949	0.90 (0.80–1.00)	0.06
Clear cell	1015	30,816	0.0994	0.0949	1.09 (0.94–1.27)	0.27
Mucinous	1000	30,816	0.0902	0.0949	0.99 (0.85–1.16)	0.91
Low-grade serous	485	30,816	0.0705	0.0949	0.76 (0.59–0.97)	0.03
First-degree family history
Ovarian cancer	483	342	0.0803	0.0849	0.87 (0.60–1.27)	0.47
Breast or ovarian cancer	477	18,442	0.0977	0.0915	1.09 (0.93–1.28)	0.28
BRCA1/2 mutation negative	346	15,492	0.1050	0.0997	1.09 (0.85–1.41)	0.49
BRCA1 mutation carriers	2332	12,433	0.0954	0.0922	1.09 (0.97–1.23)	0.14
BRCA2 mutation carriers	599	7305	0.0952	0.0966	0.89 (0.71–1.13)	0.34
Enrolled within two years of diagnosis
All invasive	10,121	30,815	0.0942	0.0949	0.99 (0.95–1.04)	0.68
BRCA1 mutation carriers	1095	10,802	0.0950	0.0940	1.05 (0.90–1.23)	0.52
BRCA2 mutation carriers	270	6509	0.0907	0.0979	0.85 (0.60–1.20)	0.36
Menopausal status
Pre- or peri-menopausal	4264	8789	0.0915	0.0927	1.02 (0.92–1.13)	0.68
Post-menopausal	11,058	15,903	0.0916	0.0951	0.99 (0.93–1.06)	0.81
Prior breast cancer
Enrolled within two years of diagnosis	426	30,815	0.0943	0.0949	0.91 (0.71–1.17)	0.46
Post-menopausal ovarian cancer	341	15,903	0.0810	0.0951	0.90 (0.68–1.21)	0.49
First degree breast or ovarian cancer family history	202	30,815	0.0916	0.0949	0.99 (0.70–1.40)	0.95
Breast cancer
All invasive	33,530	37,640	0.0904	0.0930	0.98 (0.94–1.01)	0.19
Receptor status
ER—/PR—	4009	37,043	0.0940	0.0932	1.04 (0.96–1.13)	0.36
ER—/PR—/ERBB2—	1673	28,480	0.0885	0.0947	0.97 (0.85–1.10)	0.62
First-degree family history
Breast cancer	4357	1943	0.0942	0.0954	0.96 (0.84–1.10)	0.59
Ovarian or breast cancer	4593	2265	0.0933	0.0949	0.96 (0.85–1.09)	0.52
Age diagnosis <52
ER—/PR—	1530	37,043	0.0980	0.0932	1.07 (0.95–1.22)	0.28
ER—/PR—/ERBB2—	546	27,690	0.0908	0.0948	0.99 (0.81–1.20)	0.90
BRCA1/2 mutation negative	1431	1097	0.0853	0.0925	0.91 (0.75–1.11)	0.35
BRCA1 mutation carriers	7543	7222	0.0935	0.0919	1.04 (0.97–1.12)	0.27
BRCA2 mutation carriers	4138	3766	0.1005	0.0921	1.06 (0.94–1.19)	0.35
Enrolled within two years of diagnosis
All invasive	20,444	34,349	0.0924	0.0934	0.99 (0.95–1.04)	0.73
BRCA1 mutation carriers	2595	5976	0.0896	0.0924	0.95 (0.85–1.05)	0.30
BRCA2 mutation carriers	1359	3365	0.0960	0.0926	1.05 (0.90–1.23)	0.52
Menopausal status
Pre- or peri-menopausal	7086	8642	0.0934	0.0933	0.98 (0.91–1.07)	0.70
Post-menopausal	16,346	18,605	0.0904	0.0943	0.98 (0.93–1.03)	0.36